Document is current
Any future updates will be listed below
-
Authors
Yam, Clinton
Rauch, Gaiane M.
Rahman, Tanbin
Karuturi, Meghan
Ravenberg, Elizabeth
White, Jason
Clayborn, Alyson
McCarthy, Pamela
Abouharb, Sausan
Lim, Bora
Litton, Jennifer K.
Ramirez, David L.
Saleem, Sadia
Stec, James
Symmans, W. Fraser
Huo, Lei
Damodaran, Senthil
Sun, Ryan
Moulder, Stacy L.
-
Funding
Funding for this research was provided by:
National Comprehensive Cancer Network
National Institutes of Health (N01-CM-2011-00039)
University of Texas MD Anderson Cancer Center
The Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology
Susan Papizan Dolan Fellowship in Breast Oncology
Conquer Cancer Foundation
- License Information
-
More Information
Article History
Received: 15 July 2020
Accepted: 26 August 2020
First Online: 28 September 2020
Compliance with ethical standards
:
: J.K.L. has received grant or research support from Novartis, Medivation/Pfizer, Genentech, GSK, EMD-Serono, Astra-Zeneca, Medimmune, Zenith, Jounce; participated in Speaker’s Bureau for MedLearning, Physician’s Education Resource, Prime Oncology, Medscape, Clinical Care Options; received honoraria from UpToDate; served on advisory committees or review panels for Astra-Zeneca, Ayala, Pfizer (all uncompensated), NCCN, ASCO, NIH, PDQ, SITC Breast Committee, SWOG Breast Committee. J.S. is a full-time employee and shareholder of ImmunoGen, Inc. S.L.M. has received research support from the NCCN for the clinical trial. All other authors declare that they have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
